Work

Platelet‐activating factor: a potential therapeutic target to improve cancer immunotherapy

Year: 2024
Type: article
Abstract: The tumor microenvironment (TME) fosters cancer progression by supporting the differentiation and proliferation of myeloid-derived suppressor cells (MDSCs), which play a critical role in suppressing immune responses and facilitating tumor growth. Recent findings by Dahal et al. reveal that platelet-activating factor (PAF), a lipid mediator elevated in the TME, contributes to the differentiation of neutrophils into immunosuppressive neutrophils. They showed that inhibiting PAF signaling reduces MDSC-mediated immunosuppression, thereby enhancing cytotoxic T-cell activity. This approach may improve cancer immunotherapy outcomes, particularly when combined with checkpoint blockade therapies, suggesting a promising avenue for therapeutic development.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W4404506459
FWCI: 0.417
Cites: 15
Cited by: 3
Related to: 10